Senneville E, Chidiac C, Brouillard M, Beuscart C, Leroy O, Sivery B, Beaucaire G, Mouton Y
Service Régional des Maladies Infectieuses, Centre Hospitalier, Tourcoing.
Pathol Biol (Paris). 1990 Jun;38(5 ( Pt 2)):568-71.
From January 1978 to December 1988, 54 males and 59 females were treated for varicella, zoster and disseminated zoster by varicella-zoster immunoglobulin (group I) or acyclovir (group II). 67 patients had immune deficiency disease. Treatment was successful for 92/100 patients in group I and for 100/100 patients in group II. Thrombophlebitis and renal failure were observed in group II and regressed when acyclovir was stopped. Varicella-zoster immunoglobulin and acyclovir are two effective therapeutics in the treatment of varicella and zoster in adults including immunocompromised patients. The use of acyclovir could not reduce the duration of hospitalization.
1978年1月至1988年12月期间,54名男性和59名女性因水痘、带状疱疹和播散性带状疱疹接受了水痘-带状疱疹免疫球蛋白治疗(第一组)或阿昔洛韦治疗(第二组)。67名患者患有免疫缺陷疾病。第一组100名患者中有92名治疗成功,第二组100名患者全部治疗成功。第二组观察到血栓性静脉炎和肾衰竭,停用阿昔洛韦后症状消退。水痘-带状疱疹免疫球蛋白和阿昔洛韦是治疗包括免疫功能低下患者在内的成人水痘和带状疱疹的两种有效疗法。使用阿昔洛韦并不能缩短住院时间。